GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [PSA] T2D is not what most of this community thinks it is — 65 comments in the full submission. View in context.
2.1k
c/t2dglp1·submitted 1 year ago by u/rasmus_kimani

[PSA] T2D is not what most of this community thinks it is

Discussionbranch of 15 comments

T2D is not what most of this community thinks it is — with the reasoning, because a rule without a reason gets ignored. The diabetes and obesity programmes are separate, with different populations and different primary endpoints. Reading a result across from one to the other is not a comparison. Incretin-based agents…

Read the full submission and all 65 comments →

This branch

15 comments, started 1 year ago
u/santiago_rasmussen207 points·1 year ago

Sensor accuracy varies across wear, and readings on the first day are the least reliable. Calibration practice and compression artefacts explain many alarming single values.

replysharereportpermalink
u/tired_ledger_notes57 points·1 year ago

Sensor accuracy varies across wear, and readings on the first day are the least reliable.

santiago_rasmussen is right that the fasting number moves last. Knowing that in advance saves months of worry.

replysharereportpermalink
u/chidi_abubakar74 points·1 year ago

a single high reading is not a trend

replysharereportpermalink
u/teodor_duarte39 points·1 year ago

Small fix — insulin secretion in this class is glucose-dependent, which is precisely why the risk you describe comes from the other agent.

replysharereportpermalink
u/sock_puppet_spotter34 points·1 year ago·edited

A1c is a three-month average and it lags everything

replysharereportpermalink
u/bastian_eriksen48 points·1 year ago

Kept fingersticks alongside the sensor for two weeks to sanity-check it. Worth doing once.

replysharereportpermalink
u/farid_jansen15 points·1 year ago

check the trial population before quoting a result at somebody

replysharereportpermalink
u/gentle_correctionnice about it12 points·1 year ago

Cosigning that postprandial excursions improve first and the fasting number is the laggard.

replysharereportpermalink
u/cloudy_vial_carol141 points·1 year ago

Agreed on variability. Two people with the same average can have completely different days.

replysharereportpermalink
u/tomas_lokken107 points·1 year ago

Agreed on variability.

Disagreeing with this line: that endpoint is from the obesity programme and does not answer the question.

replysharereportpermalink
u/rasmus_kimaniOP-3 points·1 year ago

How long between the two A1c measurements?

replysharereportpermalink
u/britt_abubakar64 points·1 year ago

Right, and the diabetes programmes report glycaemic endpoints. Quoting an obesity trial result here is answering a different question.

replysharereportpermalink
u/iman_castellanos53 points·1 year ago

Postprandial excursions flattened out first and the fasting number took months to follow. Nobody had told me to expect that order.

replysharereportpermalink
u/sigrid_kaufmann49 points·1 year ago

A1c, CGM, or fingersticks — which are we discussing?

replysharereportpermalink
u/marisol_moreau304 points·1 year ago

Assumed the weight endpoints from the obesity trials applied to my situation. They are different programmes.

replysharereportpermalink

← back to the whole thread

About c/t2dglp1

Type 2 diabetes as the original indication: A1c trajectories, CGM traces, hypoglycaemia risk when stacked with sulfonylureas or insulin, metformin combinations, and why the weight-loss conversation sometimes drowns out the glycaemic one.

36kmembers
62submissions
Jun 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/t2dglp1 rules
  1. Insulin and sulfonylurea interactions are a real hypo risk. Do not hand-wave them.
  2. Post A1c with units and the assay date.
  3. No medication-stopping advice. Ever.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.